On March 22, 2026, Gyre Therapeutics, Inc. reported that its subsidiary submitted a New Drug Application for Hydronidone, a treatment for chronic hepatitis B-induced liver fibrosis. This filing is significant as it marks a key step in the development of their lead product candidate.